On January 8, 2026, GRI Bio reported additional positive immune profiling data from its Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing inhibition of invariant NKT cells ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...
Morning Overview on MSN
New method could mass-produce cancer-fighting natural killer cells
Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of ...
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...
NKT has completed the construction of a new test hall, the expansion of production capacity, and a new office building at its cable accessories factory in Sweden to support the high demand for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback